+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 9 Actively Recruiting clinical trials

G

Actively Recruiting

Researchers are studying the impact and burden of three skin conditions moderate or severe alopecia areata, non-segmental vitiligo, and moderate to severe hidradenitis suppurativa. The study includes adolescents and adults and aims to understand how these conditions affect quality of life and daily functioning in a large global population. This is an observational study where participants with each condition will have a single visit for data collection following routine clinical practice. No experimental treatments are given instead, the study gathers information during this one visit to assess disease characteristics and impact. During the visit, participants will complete questionnaires and clinical assessments specific to their condition. These include tools measuring symptom impact, hair loss severity, skin depigmentation, and quality of life related to each disease. This helps researchers better understand the real-world burden of these conditions. Participation involves only this one visit, with no long-term follow-up or additional procedures.

Age: 12Years +All Genders
116 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of enpatoran in adults aged 18 to 75 with active cutaneous manifestations of lupus erythematosus, either with or without systemic disease. This global, multicenter Phase 3 study aims to understand how enpatoran works compared to a placebo in addition to standard care over a 24-week treatment period. The study is sponsored by EMD Serono Research & Development Institute, Inc. and includes participants diagnosed with Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus, andor Acute Cutaneous Lupus Erythematosus, with or without systemic lupus erythematosus. Participants are randomly assigned to receive either enpatoran tablets or matching placebo tablets taken orally twice daily for 24 weeks while continuing their standard of care treatments. The study intervention is administered as film-coated tablets, and participants are monitored throughout the treatment period. Visits occur every four weeks, with a televisit at Week 2, allowing ongoing assessment of the participants condition and response to treatment. Throughout the study, participants undergo regular evaluations including the Cutaneous Lupus Erythematosus Disease Area and Severity Index CLASI and other measures of lupus activity and symptom changes. Researchers monitor for treatment-emergent adverse events, serious adverse events, and laboratory abnormalities from Day 1 to Week 24. The primary outcome is the percentage of participants achieving a 70% or greater reduction in CLASI-A score at Week 24. Total study participation can last up to 35 weeks, including screening and follow-up assessments.

Age: 18Years - 75YearsAll GendersPhase 3
70 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of ruxolitinib cream in children aged 6 to under 12 years old who have nonsegmental vitiligo. This phase 3 study aims to understand how well ruxolitinib cream works to improve skin depigmentation in this young population. The study compares two strengths of ruxolitinib cream against a placebo cream, with participants randomly assigned to one of the groups. Participants apply either 0.75% or 1.5% ruxolitinib cream, or a matching placebo cream, as a thin layer on the affected skin areas twice daily. The treatment lasts for 24 weeks, with the primary goal of measuring improvement in facial vitiligo area. The study also monitors other outcomes such as body vitiligo improvement, patient satisfaction, and possible side effects for up to 52 weeks. During the study, participants will be regularly assessed for changes in their vitiligo using standardized scoring indexes and questionnaires that measure the impact on quality of life. Blood samples will be taken at several points to study the drugs levels in the body. Safety is closely monitored, and participants are followed through a final safety visit. Overall participation can last up to around one year, including treatment and follow-up periods.

Age: 6Years - 11YearsAll GendersPhase 3
78 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of tulisokibart in people with moderately to severely active Crohns disease. This program includes two separate studies Study 1, which involves both induction and maintenance treatment phases, and Study 2, which includes only the induction treatment phase. The main goals are to see if one or more doses of tulisokibart are better than placebo in achieving clinical remission according to specific Crohns Disease Activity Index scores or stool frequency and abdominal pain scores, and to assess endoscopic response at weeks 12 and 52 depending on the study and regulatory region. Participants receive tulisokibart either intravenously or subcutaneously at different dose levels depending on the study arm. Some receive a high dose induction followed by high or low dose maintenance, others receive low dose throughout, and some receive placebo. Extension arms allow participants who complete their original treatment to continue receiving high or low dose subcutaneous tulisokibart if they qualify. The study uses random assignment to treatment groups and is double-blind, meaning neither participants nor researchers know who receives the drug or placebo. Throughout the studies, participants undergo evaluations at specified weeks to measure clinical remission, clinical response, endoscopic response, and other outcomes such as fatigue and quality of life. Safety is monitored by tracking adverse events and discontinuations due to side effects. The overall participation may last up to 52 weeks for Study 1 and 12 weeks for Study 2, with assessments at multiple points to carefully observe treatment effects and safety.

Age: 16Years - 80YearsAll GendersPhase 3
499 locations
U

Actively Recruiting

Researchers are evaluating the Heartfelt device, a new passive monitoring system that detects early signs of fluid build-up in patients with heart failure by measuring changes in foot and lower leg volume using 3D images. The study aims to see if adding this device to standard NHS care improves quality of life and reduces heart failure-related events compared to standard care alone. The trial involves 300 participants from multiple NHS hospitals and GP practices across the UK and uses a randomized crossover design. Participants will be randomly assigned to receive either standard NHS care, which includes regular weight checks and symptom monitoring, or standard care plus the Heartfelt device installed at home. The device captures daily images of the feet to track swelling without extra effort from the user. Alerts triggered by important changes are sent to the clinical team for prompt action. Both groups receive a patient booklet from the British Heart Foundation to support self-monitoring and understanding of heart failure. During the study, participants quality of life will be assessed using questionnaires at baseline and at 3, 6, 9, and 12 months. The study will also monitor hospitalizations, deaths, medication adherence, and the availability of daily device data. Researchers will evaluate how the clinical teams respond to alerts, the ease of device use, and its cost-effectiveness. The total participation period covers 12 months of monitoring and data collection.

Age: 18Years +All GendersPhase Not Applicable
18 locations
O

Actively Recruiting

Researchers are evaluating the safety, tolerability, and effectiveness of QRX003 lotion, a 4% serine protease inhibitor, in treating Netherton syndrome NS. This study focuses on applying the lotion twice daily to affected skin areas excluding the scalp, covering about 50% or more of the body surface. The trial is conducted at multiple centers and follows an open-label design, including participants aged 4 years and older with genetically confirmed NS. Participants will apply QRX003 lotion twice daily for 12 weeks to their NS-affected skin areas. The treatment area excludes the scalp and covers approximately half or more of the body surface. This single-group study does not include a placebo or comparator group. The study spans 12 weeks of active treatment with the lotion. During the trial, participants will be monitored for improvement using several measures, including the Investigator Global Assessment IGA score to track skin condition changes, and other itch and global impression scores at week 12. Safety and tolerability will also be assessed throughout the treatment period. The total participation duration aligns with the 12-week treatment, with follow-up evaluations at the studys end.

Age: 4Years +All GendersPhase 2Phase 3
8 locations
E

Actively Recruiting

Researchers are evaluating a new blood test called Avantect to see if it can detect pancreatic cancer early in people aged 50 to 84 who have recently been diagnosed with type 2 diabetes or have elevated blood sugar levels. Pancreatic cancer is very deadly because it is often found too late for surgery, so early detection could improve treatment options. This trial aims to find out if Avantect can identify pancreatic cancer signals before symptoms appear. Participants will have their blood tested using the Avantect device at three scheduled visits over one year. If the test detects pancreatic cancer markers, participants and their doctors will be informed to arrange further imaging scans like MRI or CT to confirm the diagnosis. The study will track participants remotely for three years after consent to monitor any pancreatic cancer diagnosis or mortality through health registries. During the study, participants will provide blood samples and complete anxiety questionnaires at each visit. Researchers will assess the tests accuracy by measuring its sensitivity and specificity after three years. They will also evaluate how well the test predicts cancer presence, the stage of detected cancers, and surgery rates. The study offers free diagnostic testing and includes ongoing safety and health monitoring for all participants.

Age: 50Years - 84YearsAll GendersPhase Not Applicable
31 locations
E

Actively Recruiting

Aortic stenosis AS affects many older adults, with a rising number of people over 65 and 75 years old experiencing moderate to severe disease. This study aims to compare the benefits of early aortic valve replacement AVR versus expectant management in patients with severe asymptomatic AS. It addresses a significant gap, as no randomized controlled trials have yet compared these approaches to determine which leads to better outcomes and cost-effectiveness. Participants will be randomly assigned to either early AVR, where surgery or transcatheter AVR TAVI is planned within six months, or to expectant management, involving regular monitoring according to standard hospital practice. The study will be conducted across multiple centers in the UK, Australia, and New Zealand, with an internal pilot phase to confirm recruitment feasibility. Those in the AVR group may undergo additional tests such as coronary angiography, with further treatment decisions made by their care team. During the study, participants will be followed for a median of 5.5 years, with assessments including cardiovascular events, hospitalizations, quality of life questionnaires, and health economics evaluations. Researchers will measure a combined outcome of cardiovascular death, heart failure hospitalization, and stroke, along with other health and disability measures. The study will use intention-to-treat analysis, ensuring participants are evaluated in their assigned groups regardless of treatment received.

Age: 18Years +All GendersPhase Not Applicable
110 locations
I

Actively Recruiting

This research aims to compare two standard care approaches in very premature infants born before 30 weeks to see if withholding enteral feeds around the time of blood transfusion reduces the risk of Necrotizing Enterocolitis NEC, a serious intestinal disease. NEC can severely damage the bowel and has a high risk of death or long-term health problems. The study involves infants from neonatal intensive care units in Canada and the UK and evaluates if withholding or continuing feeds during transfusion affects outcomes. The study randomly assigns infants to one of two groups one where all enteral feeds are stopped for 4 hours before, during, and after packed red cell transfusion and another where feeding continues as usual throughout the transfusion period. Infants will remain on their assigned feeding strategy until reaching 34 weeks and 6 days gestational age. During feed withholding, hydration and blood sugar are maintained by parenteral nutrition or intravenous glucose according to local practice. Participants will be monitored from randomization until 40 weeks postmenstrual age for the development and severity of NEC, death, infections, nutritional support duration, growth, and other health outcomes. Researchers will track feeding practices, transfusions, and clinical events, with long-term follow-up until discharge from the hospital. The study intends to identify which feeding approach during transfusion might better prevent NEC in these vulnerable infants.

Age: 0 - 30WeeksAll GendersPhase Not Applicable
40 locations